TouchIMMUNOLOGY got the opportunity to catch up with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, US) around the use of roflumilast in the treatment of chronic plaque psoriasis patients (Clinical Trial Identifier: NCT04211363 & NCT04211389).
The abstract ‘Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety from DERMIS-1 and DERMIS-2 Phase 3 trials‘ (Presentation ID: FC01.04) was presented at the EADV Spring Symposium 2021, 6-7 May 2021.
Questions
- Could you tell us a little about the health burden and unmet needs in the topical treatment of plaque psoriasis? (0:17)
- What is the rationale for the use of roflumilast and how does it compare with the other FDA-approved PDE4 inhibitors? (1:11)
- What were the aims, design and inclusion criteria of the DERMIS-1 and DERMIS-2 studies? (1:44)
- What were the primary outcome measures of the study and how well were these achieved? (2:42)
- What other findings were there? (3:25)
Disclosures: Linda Stein Gold discloses being an investigator/advisor for Arcutis, Dermavant, Incyte, Ortho, Galderma, Abbvie, Leo, UBB, BMS.
Support:Â Interview and filming supported by Touch Medical Media.
Filmed as a highlight of EADV Spring 2021 (Virtual).
